- Home
- HALO vs ABVX Comparison
HALO vs ABVX Comparison
Compare HALO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HALO | ABVX |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.7B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | HALO | ABVX |
|---|---|---|
| Price | $66.60 | $126.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $78.64 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 1.2M | 761.4K |
| Earning Date | 05-05-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.56 | N/A |
| Revenue | ★ $151,862,000.00 | N/A |
| Revenue This Year | $28.24 | $52.14 |
| Revenue Next Year | $12.56 | $4,132.27 |
| P/E Ratio | $25.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.50 | $5.59 |
| 52 Week High | $82.22 | $148.83 |
Technical Indicators
Market Signals| Indicator | HALO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 60.75 |
| Support Level | $63.85 | $107.29 |
| Resistance Level | $68.00 | $129.84 |
| Average True Range (ATR) | 1.98 | 5.04 |
| MACD | 0.03 | 1.17 |
| Stochastic Oscillator | 61.46 | 91.37 |
Price Performance
Historical ComparisonAbout HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.